Beam Therapeutics (NASDAQ:BEAM) Issues Quarterly Earnings Results

Key Points

• Beam beat expectations with EPS of ($0.91) versus the ($1.03) consensus and revenue of $31.74M—up 323% year-over-year and well above the $10.98M estimate—though the company remains unprofitable (negative ROE of 30.65% and net margin of -57.24%).
• Shares dipped about 2.7% to $31.47 after the release; the stock has a market cap of $3.23B and a 12‑month trading range of $15.35 to $36.44.
• Analysts and insiders diverge: the consensus is a "Moderate Buy" with an average target of $47.17 (price targets range roughly $26–$65), while insiders sold ~79,544 shares (~$1.9M) in the quarter under Rule 10b5‑1 plans to cover tax withholdings.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) released its earnings results on Thursday. The company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.12, FiscalAI reports. Beam Therapeutics had a negative return on equity of 30.65% and a negative net margin of 57.24%.The company had revenue of $31.74 million for the quarter, compared to analysts' expectations of $10.98 million. During the same quarter in the previous year, the firm posted ($1.23) EPS. The firm's quarterly revenue was up 323.2% on a year-over-year basis.

Beam Therapeutics Trading Down 2.7%

Shares of NASDAQ:BEAM traded down $0.87 during trading on Thursday, hitting $31.47. 1,755,639 shares of the stock were exchanged, compared to its average volume of 2,191,142. The company has a fifty day moving average price of $27.21 and a two-hundred day moving average price of $27.07. The company has a market cap of $3.23 billion, a PE ratio of -31.16 and a beta of 2.26. Beam Therapeutics has a 12-month low of $15.35 and a 12-month high of $36.44.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on BEAM. Wall Street Zen upgraded Beam Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th. Royal Bank Of Canada boosted their price target on Beam Therapeutics from $22.00 to $26.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 25th. UBS Group began coverage on Beam Therapeutics in a research note on Wednesday, January 7th. They set a "neutral" rating and a $28.00 price target on the stock. Tudor Pickering set a $41.00 price target on Beam Therapeutics in a research note on Wednesday, January 21st. Finally, Wedbush boosted their price target on Beam Therapeutics from $57.00 to $65.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $47.17.

Insider Transactions at Beam Therapeutics

In related news, insider Christine Bellon sold 5,956 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total value of $146,398.48. Following the sale, the insider owned 109,711 shares of the company's stock, valued at approximately $2,696,696.38. This represents a 5.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Amy Simon sold 6,700 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $24.58, for a total value of $164,686.00. Following the completion of the sale, the insider directly owned 102,735 shares in the company, valued at approximately $2,525,226.30. The trade was a 6.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 79,544 shares of company stock worth $1,899,942 over the last quarter. Insiders own 3.80% of the company's stock.

Institutional Investors Weigh In On Beam Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Larson Financial Group LLC lifted its stake in Beam Therapeutics by 4,370.5% in the 3rd quarter. Larson Financial Group LLC now owns 1,967 shares of the company's stock valued at $48,000 after buying an additional 1,923 shares in the last quarter. Van ECK Associates Corp lifted its stake in Beam Therapeutics by 48.7% in the 3rd quarter. Van ECK Associates Corp now owns 2,158 shares of the company's stock valued at $52,000 after buying an additional 707 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in Beam Therapeutics in the 4th quarter valued at approximately $59,000. Daiwa Securities Group Inc. lifted its stake in Beam Therapeutics by 1,248.8% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,817 shares of the company's stock valued at $65,000 after buying an additional 3,534 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. purchased a new stake in Beam Therapeutics in the 4th quarter valued at approximately $69,000. Hedge funds and other institutional investors own 99.68% of the company's stock.

Beam Therapeutics Company Profile

Beam Therapeutics, Inc NASDAQ: BEAM is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.